Dapagliflozin
- Introduction
- Newest Products
Introduction
Dapagliflozin
Dapagliflozin is the first approved SGLT2 inhibitor for the treatment of type II diabetes, which is used to improve glycemic control as an adjunct to dietary and exercise for adults with type II diabetes.
Newest Products
| Image | Part # | Description | manufacturer | Stock | RFQ | |
|---|---|---|---|---|---|---|
|
|
Dapagliflozin (461432-26-8) |
CAS: 461432-26-8; Dapagliflozin manufaturer; Dapagliflozin API; Diabetics
|
|
In Stock
|
|
|
|
|
Dapagliflozin Tetraacetate (461432-25-7) |
CAS: 461432-25-7; Dapagliflozin manufaturer; Dapagliflozin intermediate; Diabetics
|
|
In Stock
|
|
|
|
|
1-Chloro-2-(4-ethoxybenzyl)-4-iodobenzene (1103738-29-9) |
CAS: 1103738-29-9; Dapagliflozin manufaturer; Dapagliflozin intermediate; Diabetics
|
|
In Stock
|
|
|
|
|
5-bromo-2-chloro-4'-ethoxydiphenylmethane (461432-23-5) |
CAS: 461432-23-5; Dapagliflozin manufaturer; Dapagliflozin intermediate; Diabetics
|
|
In Stock
|
|
